2627 Hanover St
4 articles about Juvena Therapeutics
Juvena Therapeutics Bolsters Leadership Team With Key Industry Veterans in Drug Discovery and Development, Data Science, and Business Development
Juvena Therapeutics , Inc. announced today the hiring of four senior leaders with significant industry experience in both small and large pharmaceutical and biotech companies.
Juvena Therapeutics pulled in $41 million in Series A financing to advance research into the therapeutic potential of secreted proteins to target chronic and age-related diseases.
Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases
Juvena Therapeutics, Inc. announced today that it has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million.
Juvena Therapeutics Awarded Highly Competitive CIRM Grant To Advance Lead Program, JUV-161, To Treat Myotonic Dystrophy Type 1
Juvena Therapeutics today announced that the company has been awarded a highly competitive translational grant from the California Institute of Regenerative Medicine (CIRM), totaling $3,906,376.